A Comparison Between the Therapeutic Effect of Metformin Alone versus a Combination Therapy with Insulin in Uncontrolled, Non-Adherence Patients with Type 2 Diabetes: Six Months Follow-Up.
effectiveness of the treatment
insulin
metformin
non-adherence
type 2 diabetes
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2021
2021
Historique:
received:
03
05
2021
accepted:
22
06
2021
entrez:
21
7
2021
pubmed:
22
7
2021
medline:
22
7
2021
Statut:
epublish
Résumé
The study aimed to compare the metabolic effects of an intensive dose of metformin alone among non-adherence patients with type 2 diabetes versus in combination with insulin among adherence patients. The prospective cohort study was carried out on a sample of 140 patients above 18 years old, divided into two groups. The first group (n=70) was recommended metformin monotherapy in an intensive dose of 2-3 g/day, whereas the second group (n=70) was prescribed metformin (1-2g/day) in combination with insulin. FPG, HbA1c, BMI, blood pressure, TC, TG, HDL-C, LDL-C, creatinine, and eGFR were measured for each patient at baseline and after a follow-up of 6 months of active treatment. After six months of active treatment using monotherapy with an intensive dose of metformin, only 11.43% of patients achieved the target levels of HBA1c below 7%. In the group of patients treated using a combination of metformin with insulin, after six months of active treatment, 45.72% achieved HBA1c levels below 7% (p<0.0001). Compared with an intensive dose of metformin alone, the combination of insulin and metformin was associated with improved glycemic control (change of fasting blood glucose: 2.49 mmol/l vs 1.30 mmol/l, p=0.0016). Metformin use alone, as compared with insulin, was associated with a significant increase in HDL-C (+0.03 mmol/l vs -0.14 mmol/l, p=0.0485). Increased baseline obesity and increased baseline glycemia were the factors related to the likelihood of failing to achieve the target levels for HbA1c. Metformin proved to be more effective in controlling hyperglycemia when combined with insulin therapy. Our study shows how many health benefits loss patients who, despite systematic diabetes education, do not agree to change their treatment in the form of adding a second drug, including insulin.
Identifiants
pubmed: 34285531
doi: 10.2147/DMSO.S317659
pii: 317659
pmc: PMC8286717
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3243-3252Informations de copyright
© 2021 Paczkowska et al.
Déclaration de conflit d'intérêts
The authors reported no conflicts of interest for this work.
Références
Diabetes Care. 2002 Dec;25(12):2133-40
pubmed: 12453950
Diabetes Obes Metab. 2011 Sep;13(9):814-22
pubmed: 21481127
Ann Intern Med. 1999 Aug 3;131(3):182-8
pubmed: 10428734
J Diabetes Complications. 2010 Mar-Apr;24(2):84-9
pubmed: 19282203
Int J Mol Sci. 2020 Aug 30;21(17):
pubmed: 32872570
N Engl J Med. 1995 Aug 31;333(9):541-9
pubmed: 7623902
Diabetes Obes Metab. 2016 Jan;18(1):92-5
pubmed: 26435375
Patient Prefer Adherence. 2013 Jul 10;7:675-82
pubmed: 23874088
J Family Community Med. 2012 Jan;19(1):26-32
pubmed: 22518355
Br J Clin Pharmacol. 2012 May;73(5):691-705
pubmed: 22486599
JAMA. 1999 Jun 2;281(21):2005-12
pubmed: 10359389
Diabetologia. 2017 Sep;60(9):1577-1585
pubmed: 28776086
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
BMJ. 2012 Apr 19;344:e1771
pubmed: 22517929
Diabetes Care. 1998 Jan;21(1):87-92
pubmed: 9538975
Diabetes Care. 2011 Jun;34(6):1249-57
pubmed: 21617109
Am J Manag Care. 2003 Feb;9(2):155-71
pubmed: 12597603
PLoS One. 2018 Nov 26;13(11):e0207947
pubmed: 30475888
Diabetes Care. 1993 Oct;16(10):1387-90
pubmed: 8269798
World J Diabetes. 2015 Jun 25;6(6):850-67
pubmed: 26131326
Pharmacogenet Genomics. 2012 Nov;22(11):820-7
pubmed: 22722338
Diabetes Care. 2009 Jan;32 Suppl 1:S62-7
pubmed: 19118289
Diabetes. 1995 Aug;44(8):968-83
pubmed: 7622004
Braz J Med Biol Res. 2006 Apr;39(4):489-94
pubmed: 16612472
Lancet. 2008 May 24;371(9626):1753-60
pubmed: 18502299
Scand J Clin Lab Invest. 2017 Apr;77(2):104-108
pubmed: 28097881
Metabolism. 2001 Dec;50(12):1457-61
pubmed: 11735093
J Intern Med. 2004 Jul;256(1):1-14
pubmed: 15189360
Clin Chem. 1990 Jan;36(1):36-42
pubmed: 2297935
Diabetes Res Clin Pract. 1995 May;28(2):103-17
pubmed: 7587918
Diabetes. 2000 Dec;49(12):2094-101
pubmed: 11118012
Oman Med J. 2012 Jul;27(4):269-73
pubmed: 23071876
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
J Hypertens. 2017 Jan;35(1):18-26
pubmed: 27607453
Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):323-9
pubmed: 25105996
Med J Armed Forces India. 1998 Apr;54(2):131-133
pubmed: 28775446
Diabetes. 2000 Dec;49(12):2063-9
pubmed: 11118008
Eur J Clin Pharmacol. 1993;44(2):107-12
pubmed: 8453955
BMJ. 2001 Apr 21;322(7292):981-5
pubmed: 11312235